Researchers have identified an enzyme key to stopping tumor growth in renal cell carcinoma.
Patients with multiple myeloma experienced survival benefits when treated autologous stem-cell transplantation after induction therapy.
Janssen Biotech, Inc. will begin a new phase III trial of daratumumab, which will treat patients with multiple myeloma.
European health authorities bought nearly 500,000 more biopsy needles for breast cancer at 60% of the amount spent in the US.
Researchers have discovered how MEK and MET causes resistance to treatment for cancer cells.
Health sector prices explain much of difference between U.S. and other high-spending countries.
Millions signing up for Medicaid to comply with federal health care law.
Almost 80% of doctors in the United States have switched from paper to electronic health records.
Most physicians believe that doctors order too many medical tests, yet half admit to doing so themselves in response to a patient who insists, a new survey shows.
Several modifiable risk factors can cut chronic disease deaths over the next 15 years.
Caucasian women overestimate their risk of breast cancer while African American and Hispanic women underestimate their risk, according to research presented at BCS 2013.
A survey presented at BCS 2013 has found a number of factors that cause rural US women to avoid breast cancer screening.
The benefit of perioperative MRI for women with ductal carcinoma in situ (DCIS) is "uncertain," found a study presented during BCS 2013.
ChemotherapyAdvisor.com Editorial Board member Dr. Edith Perez of the Mayo Clinic, Jacksonville, FL, recommends high impact abstracts at the Breast Cancer Symposium 2013.
Women who underwent radiation for ductal carcinoma in situ do not face an increased risk of cardiovascular disease, found a study presented at BCS 2013.
Patients with substance use disorder are more likely to be hospitalized and to make emergency department visits.
Experts note study findings aren't definitive, and risk is minimal.
Current smoking and smoking cessation prior to diagnosis does not alter risk of recurrence or progression of non-muscle-invasive bladder cancer.
Study finds a 19% increased risk of distant metastases or death from the cancer.
Those with depression, intermediate- or high-risk disease undergo less treatment.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|